Plexxikon
{{Short description|American drug discovery company}}
{{Infobox company
| name = Plexxikon
| type = Subsidiary
| industry = Biotechnology
| fate = Acquired by the Daiichi Sankyo
| founded = {{Start date|2001}}
| founder = Joseph Schlessinger
| defunct = {{End date and age|2011}}
| hq_location = South San Francisco, California, United States.
}}
Plexxikon is an American drug discovery company based in South San Francisco, California. It was co-founded in 2001 by Joseph Schlessinger of Yale University, and Sung-Hou Kim of the University of California, Berkeley.
It uses a proprietary structural biology-based platform called Scaffold-Based Drug Discovery to build a pipeline of products in multiple therapeutic areas. This discovery process integrates multiple technologies, including structural screening as one key component, that it hopes will give a significant competitive advantage over other approaches.{{Citation needed|date=August 2022}}{{Cite web |title=AI Drug Discovery: Key Trends and Developments in Pharmaceutical Industry |url=https://www.biopharmatrend.com/post/615-pharmaceutical-artificial-intelligence-key-developments-in-2022/ |access-date=2023-09-11 |website=www.biopharmatrend.com |language=en}}
In April 2011, Plexxikon was acquired by the Japanese pharmaceutical company Daiichi Sankyo for $805 million and an additional $130 million in potential milestone payments.{{cite web|title=Daiichi Sankyo to Acquire Plexxikon|url=http://www.plexxikon.com/view.cfm/88/Press-Releases |date=2011-02-28 |publisher=Plexxikon |archive-url=https://web.archive.org/web/20110306091816/https://www.plexxikon.com/view.cfm/88/Press-Releases |archive-date=2011-03-06 |url-status=dead}}{{Cite web|date=2011-03-03|title=Plexxikon acquired by Daiichi Sankyo|url=https://biopharmconsortium.com/2011/03/03/plexxikon-acquired-by-daiichi-sankyo/|access-date=2020-08-06|website=Haberman Associates|language=en-US}}{{Cite web|title=Daiichi Sankyo, Inc. Completes Plexxikon Inc. Acquisition|url=https://www.biospace.com/article/daiichi-sankyo-inc-completes-plexxikon-inc-acquisition-/|access-date=2020-08-06|website=BioSpace|language=en-US}}
Daiichi Sankyo announced the shutdown of Plexxikon in 2022.{{Cite web|first=Madeline |last=Wells|date=2022-01-12|title=South SF company bought for $800 million is being shut down|url=https://www.sfgate.com/local/article/South-SF-Plexxikon-to-shut-down-16770179.php|website=SFGATE|language=en-US |archive-url=https://web.archive.org/web/20220112185128/https://www.sfgate.com/local/article/South-SF-Plexxikon-to-shut-down-16770179.php |archive-date=2022-01-12 |url-status=live}}
Drug pipeline
- Vemurafenib (Zelboraf) and pexidartinib (Turalio) are two FDA approved drugs developed by Plexxikon
- Plexxikon is collaborating with Wyeth Pharmaceuticals on several products for use in type II diabetes and other metabolic disorders.{{Cite web|last=|first=|date=28 October 2004|title=Wyeth, Plexxikon tie up to develop novel diabetes & metabolic disorders treatment|url=http://www.pharmabiz.com/article/detnews.asp?SecArch=&articleid=24409§ionid=14|url-status=dead|archive-url=https://web.archive.org/web/20071024140445/http://www.pharmabiz.com/article/detnews.asp?SecArch=&articleid=24409§ionid=14|archive-date=24 October 2007|access-date=|website=}} The most advanced of these agents is indeglitazar (PLX204), which is currently in Phase II clinical trials for type 2 diabetes.{{Cite journal|last=|first=|date=18 December 2007|title=Study Evaluating PPM-204 In Subjects With Type 2 Diabetes - Full Text View - ClinicalTrials.gov|url=https://clinicaltrials.gov/ct2/show/NCT00425919|archive-url=|archive-date=|access-date=2020-10-09|website=Clinical Trials|language=en}}
- PLX7486 is a CSF1R antagonist and pan-TRK inhibitor in clinical trials for advanced solid tumors.{{Cite web | url = https://www.cancer.gov/publications/dictionaries/cancer-drug/def/fms-trk-tyrosine-kinase-inhibitor-plx7486 | title = Fms/Trk tyrosine kinase inhibitor PLX7486 | work = NCI Drug Dictionary | publisher = National Cancer Institute }}{{Cite journal|date=2018-08-02|title=Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors|url=https://clinicaltrials.gov/ct2/show/NCT01804530|url-status=live|archive-url=https://web.archive.org/web/20211117224901/https://clinicaltrials.gov/ct2/show/NCT01804530|archive-date=2021-11-17|website=ClinicalTrials.gov}}